Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: Results of a thorough QT Study (TQTS) with QT-concentration analysis

Journal of Clinical Pharmacology

Volumn 52, Issue 6, 2012, Pages 893-903

  Tyl, Benoît ^a   Kabbaj, Meriam ^b   Azzam, Sara ^e   Sologuren, Ander ^c   Valiente, Román ^c   Reinbolt, Elizabeth ^b   Roupe, Kathryn ^d   Blanco, Nathalie ^e   Wheeler, William ^b  

^a Department of Cardiology   (France)

^b CELERION   (United States)

^c FAES FARMA   (Spain)

^d CEDRA Corporation   (United States)

^e Centralized Cardiac Services   (France)

Author keywords

baseline; bilastine; ketoconazole; moxifloxacin; QT correction; QT concentration; thorough QT study

Indexed keywords

BILASTINE; KETOCONAZOLE; MOXIFLOXACIN; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEART; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PR INTERVAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; T WAVE;

ADULT; ANTI-ALLERGIC AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; FEMALE; HALF-LIFE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; KETOCONAZOLE; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; PIPERIDINES; YOUNG ADULT;

EID: 80052017819     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011407191     Document Type: Article

References (35)

1. Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D. 2005 ; 6: 371-384
2. García-Gea C, Martínez-Colomer J, Antonijoan RM, Valiente R, Barbanoj M. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol. 2008 ; 28: 675-685
3. Day J. Pros and cons of the use of antihistamines in managing allergic rhinitis. J Allergy Clin Immunol. 1999 ; 103: S395 - S399
4. Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009 ; 64: 158-165
5. Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy. 2009 ; 39: 1338-1347
6. Horak F, Zieglmayer P, Zieglmayer R, Lemell P. The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm Res. 2010 ; 59: 391-398
7. Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010 ; 65: 516-528
8. Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy. 2010 ; 65: 1-13
9. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA. 1990 ; 264: 2788-2790
10. Morris LS, Carlson A. Protecting patients from harm: terfenadine and potential drug therapy interactions. Drug Inf J. 1998 ; 32: 339-345
11. European Medicines Agency. EMEA ICH Topic E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. CHMP/ICH 2005, 2/04. London: European Medicines Agency; 2005. http://www.emea.europa.eu/pdfs/human/ich/000204en.pdf. Accessed April 26, 2011.
12. Morganroth J. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol. 2004 ; 37: 25-29
13. Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol. 2002 ; 54: 188-202
14. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003 ; 89: 1363-1372
15. Malik M, Farbom P, Batchvarov V, Hnatkova K, Camm AJ. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 2002 ; 87: 220-228
16. Cheng B, Chow SC, Burt D, Cosmatos D. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables. J Biopharm Stat. 2008 ; 18: 494-501
17. Garnett CE, Beasley N, Bhattaram VA, et al. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008 ; 48: 13-18
18. Kligfield P, Tyl B, Maarek M, Maison-Blanche P. Magnitude, mechanism, and reproducibility of QT interval differences between superimposed global and individual lead ECG complexes. Ann Noninvasive Electrocardiol. 2007 ; 12: 145-152
19. Tyl B, Azzam S, Reinbolt E, Blanco N, Olbertz J, Wheeler W. Choice of baseline in a multiple-dose thorough QT study (TQTS)-effect on analysis of moxifloxacin-induced QTc prolongation. OAJCT. 2009 ; 2: 1-7
20. European Medicines Agency. EMEA ICH Topic E14: Questions and Answers. CHMP/ICH. 2008. London: European Medicines Agency; 2008. http://www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002878.pdf. Accessed April 26, 2011.
21. Natekar M, Hingorani P, Gupta P, et al. Effect of number of replicate electrocardiograms recorded at each time point in a thorough QT study on sample size and study cost. J Clin Pharmacol. 2010 ;:
22. Darpo B, Agin M, Kazierad DJ, et al. Man versus machine: is there an optimal method for QT measurements in thorough QT studies?. J Clin Pharmacol. 2006 ; 46: 598-612
23. Tyl B, Kabbaj M, Fassi B, De Jode P, Wheeler W. Comparison of semiautomated and fully automated methods for QT measurement during a thorough QT/QTc study: variability and sample size considerations. J Clin Pharmacol. 2009 ; 49: 905-915
24. Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: Part I. The electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol. 2007 ; 49: 1109-1127
25. Funck-Brentano C, Jaillon P. Rate-corrected QT interval: techniques and limitations. Am J Cardiol. 1993 ; 72: 17B - 22B
26. Couderc JP, Xiaojuan X, Zareba W, Moss AJ. Assessment of the stability of the individual-based correction of QT interval for heart rate. Ann Noninvasive Electrocardiol. 2005 ; 10: 25-34
27. Iwamoto M, Kost JT, Mistry GC, et al. Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval. J Clin Pharmacol. 2008 ; 48: 726-733
28. Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol. 2007 ; 63: 1011-1017
29. Mason JW, Florian JA, Garnett CE, Moon TE, Selness DS, Spaulding RR. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies. J Clin Pharmacol. 2010 ; 50: 1249-1259
30. Chaikin P, Gillen MS, Malik M, Pentikis H, Rhodes GR, Roberts DJ. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. Br J Clin Pharmacol. 2005 ; 59: 346-354
31. Robert M, Salvà M, Segarra R, et al. The prokinetic cinitapride has no clinically relevant pharmacokinetic interaction and effect on QT during coadministration with ketoconazole. Drug Metab Dispos. 2007 ; 35: 1149-1156
32. Johnson BM, Adams LM, Zhang K, et al. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol. 2010 ; 50: 951-959
33. Daneshmend TK, Warnock DW, Turner A, Roberts CJC. Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother. 1981 ; 8: 299-304
34. Crean C, Sologuren A, Valiente R, McLaverty D. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics. 8th Congress of the European Association of Clinical Pharmacology and Therapeutics. Basic Clin Pharmacol Toxicol. 2007 ; 101: 148-149
35. Bilbao Spain: ; 2010 :